There's no question that diabetes is on the rise worldwide. The World Health Organization estimates that diabetes will be the seventh leading cause of death in 2030. Up to 25% of this population will get a foot ulcer at some point in their life.
Up until now, the origin of aggressive ovarian cancer has eluded scientists. But researchers at Cornell University have discovered the source of stem cell-like cells that can give rise to ovarian cancer in mice.
Researchers from the Oregon Health & Science University Doernbecher Children's Hospital claim to have developed a method to grow liver stem cells in culture, a breakthrough that could be significant in advancing hepatitis research, transplantation for cirrhosis and other chronic liver conditions, and for conducting drug-metabolism and toxicity studies.
Eleven scientists have been named winners of the Breakthrough Prize in Life Sciences prize. The scientists, whose specialties include genetics, stem cells and cancer, will receive $3 million each to pursue scientific projects.
The first clinical study to put induced pluripotent stem (iPS) cells into humans is soon to get under way in Japan, where an institutional review board at the Institute for Biomedical Research and Innovation gave conditional approval.
Bone marrow stem cells may provide a way to target and treat inactive tuberculosis, which can hide in the body and emerge later on down the road, well after aggressive drug therapy.
Embryonic stem cell research has yet to live up to all the hype. So far, human embryonic stem cells, or hESCs, haven't yielded any cures or therapies to treat diseases. Read more >>
Stem cell research with rats may provide hope to stroke victims. In rats, stem cells repaired brain and nerve damage after a stroke, returning the animals to near normal within just a couple of weeks.
The La Jolla, CA-based Salk Institute for Biological Studies has landed a $42 million grant to establish the Helmsley Center for Genomic Medicine. The award, from The Leona M. and Harry B. Helmsley Charitable Trust, is the biggest in Salk's history.
Stem cell-based therapeutics are a fast-growing area of early-stage biotech research, but they need better production methods to enable large-scale R&D.